[Business Wire] , During the 33rd Annual J.P. Morgan Healthcare Conference on January 12, 2015 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2014 financial results and an updated financial outlook. The presentation can be accessed live by webcast and the financial data will be made available in the Investor Relations section of the Company’s website at www.celgene.com. To view the full article click here.
Celgene Corporation (CELG), On 10/23/2014, CELG reported 3 quarter 2014 earnings of $0.97 per share. This result was in-line with the consensus of the 24 analysts following the company and beat last year’s 3 quarter results by 24.36%.
Insufficient price earnings data. CELG’s PE ratio is among the highest of any stock in the Biotechnology & Drugs industry and signals that investors have high hopes for this company’s future business prospects.
Celgene Corporation (CELG)‘s PE ratio is among the lowest of any stock in the Semiconductors industry and signals that investors have not been willing to pay a premium for this company’s business prospects. Additionally, during the past year, earnings growth has outpaced its historical five year growth rate.
In terms of ratings, there are twenty four analysts that cover the stock which have provided Q4 2014 earnings per share estimates. The consensus anticipated number for the upcoming quarter is $0.99. The highest estimate is $1.05 while the lowest is $0.89. The company has a one year EPS growth rate of 2%.
Celgene Corporation (NASDAQ:CELG) is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.